Proven Science

Syntimmune is based on more than 25 years of insights into the crucial and complex role of FcRn in regulating pathogenic IgG and immune complexes that drive many autoimmune diseases. The company is leveraging this expertise to develop medicines with broad potential to address a wide range of autoimmune diseases.

The FcRn receptor – once thought to exist only in newborn rodents – is now recognized as a highly potent immuno-stimulatory molecule that functions throughout human life. Syntimmune’s scientific founders have shown that FcRn plays a key role in multiple autoimmune diseases.

FcRn
FcRn

FcRn RECYCLES AND PROLONGS HALF-LIFE OF IgG

Antibodies play an important role in a healthy body’s defense by fighting infections from bacteria and other invaders. In autoimmune diseases, however, the body mistakenly attacks its own tissues through the production of pathogenic (disease-causing) antibodies of the Immunoglobulin G (IgG) subtype.

FcRn rescues IgGs from lysosomal degradation by binding them to endosomes and returning them to the bloodstream. This helps prolong the half-life of IgG. In health, this function contributes to a normal immune response. In many autoimmune conditions, however, FcRn prevents lysosomal degradation of pathogenic IgGs that drive disease. Blocking the FcRn-IgG interaction has the potential to generate a potent therapeutic response.

FcRn CONTRIBUTES TO INFLAMMATORY IMMUNE RESPONSES

FcRn plays an important role in antigen processing and presentation, contributing to activation of CD4+ and CD8+ T cells and in turn stimulating the production and release of inflammatory cytokines by these cells. FcRn-mediated antigen presentation is also implicated in the production of IgG by B cells and perpetuating the IgG immune response. In healthy bodies, these processes are beneficial. In patients with autoimmune disease, however, these processes can induce harmful inflammation and increased levels of pathogenic IgG.
IgC Graphic

Syntimmune’s investigational lead candidate, SYNT001, has broad potential applicability in IgG-mediated autoimmune diseases. These diseases can be chronic and life-threatening, and current treatments can have numerous limitations, including significant adverse effects and delayed or non-durable response.

HEMATOLOGY
  • Warm Autoimmune Hemolytic Anemia
  • Idiopathic Thrombocytopenic Purpura
  • Anti-Phospholipid Syndrome
NEPHROLOGY
  • Membranous Glomerulus Nephropathy
  • Lupus Nephritis
DERMATOLOGY
  • Pemphigus
  • Bullous Pemphigoid/Mucous Membrane Pemphigoid
  • Dermatomyositis
  • Scleroderma
RHEUMATOLOGY
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
NEUROLOGY
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Myasthenia Gravis
  • Guillain-Barré Syndrome